Supplementary information GES-1 AGS **BGC-823** HGC-27 SGC-7901 MGC-803 80 NC В siRNA-circRNA0000096 Cell cycle distribution (%) 0 Glar 2 6/0' S

Supplementary Figure 1. Cell cycle distributions in a human normal gastric epithelial cell line and human gastric cancer cell lines following by knockdown of hsa_circ_0000096.

BGC-823

AGS

GES-1

Normal Cell


SGC-7901

MGC-803


HGC-27

Cancer cells


(A) Representative flow cytometry results. (B) Data are presented as mean \pm SD, n=3. NC, negative control. *p<0.05, **p<0.01, ***p<0.001.





Supplementary Figure 2. Cell apoptosis in a human normal gastric epithelial cell line (A) and human gastric cancer cell lines BGC-823 (B), SGC-7901 (C), AGS (D), HGC-27 (E), and MGC-803 (F) following by knockdown of hsa circ 0000096.




Supplementary Figure 3. The effect of knockdown of has_circ_0000096 on tumor growth of human gastric cancer cell lines BGC-823 (A) and MGC-803 (B)








Supplementary Figure 4. The result of protein levels in xenografts nude mice models. CDK6 (A), cyclin D1 (B), MMP-2 (C), MMP-9 (D), Ki67 (E), VEGF (F), and E-cadherin (G). The plotting scale is $500\mu m$. (H) Data are presented as mean \pm SD, n=3. NC, negative control. *p<0.05, **p<0.01, ***p<0.001.





Supplementary Figure 5. The expression level of miR-224 (A) and miR-200a (B) in human normal gastric epithelial cell line and human gastric cancer cell lines following by knockdown of hsa_circ_0000096. Data are presented as mean \pm SD, n=3. NC, negative control. *p<0.05, **p<0.01, ***p<0.001.

Supplementary Table 1. The relationship of hsa_circ_0000096 expression levels (ΔC_t) in cancer tissues with clinicopathological factors of patients with gastric cancer

Characteristics	No. of patients (%)	$Mean \pm SD$	p value
Age (year)			
≥ 60	59 (61.5)	13.20 ± 1.36	0.124
< 60	37 (38.5)	12.73 ± 1.41	
Gender			
Male	70 (72.9)	13.21 ± 1.40	0.001
Female	26 (27.1)	12.28 ± 1.21	
Diameter (cm)			
≥ 5	53 (55.2)	13.05 ± 1.52	0.315
< 5	43 (44.8)	12.79 ± 1.26	
CA19-9			
Positive	55 (57.3)	13.04 ± 1.51	0.497
Negative	41 (42.7)	12.80 ± 1.26	
CEA			
Positive	88 (91.7)	12.97 ± 1.42	0.327
Negative	8 (8.3)	12.54 ± 1.32	
Differentiation			
Well	6 (6.4)	12.83 ± 1.06	0.441
Moderate	47 (50.0)	13.06 ± 1.42	
Poor	41 (43.6)	12.80 ± 1.42	
Lymphatic metastasis			
N0	34 (33.3)	13.27 ± 1.25	0.201
N1	13 (13.5)	12.70 ± 1.24	
N2	15 (13.6)	12.97 ± 1.62	
N3	34 (35.4)	12.65 ± 1.53	
Distal metastasis			
M0	88 (91.7)	13.00 ± 1.42	0.153
M1	8 (8.3)	12.33 ± 1.16	
Invasion			
Tis & T1-T3	36 (37.5)	13.30 ± 1.29	0.046
T4	60 (64.5)	12.73 ± 1.44	
TNM stage			
0 & I & II	38 (39.6)	13.33 ± 1.30	0.024
III & IV	58 (60.4)	12.63 ± 1.142	